Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs Fluticasone/Salmeterol in Moderate to Severe COPD
NCT01315249Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0-12 Hours at 26 weeks. Started Mar 2011; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01315249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315249.